Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene... see more

Recent & Breaking News (OTCPK:TSOI)

Therapeutic Solutions International Granted Broad Patent on Treatment of Neurodegenerative Conditions

Business Wire November 28, 2022

Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Business Wire November 14, 2022

Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)

Business Wire November 9, 2022

Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy

Business Wire November 7, 2022

Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Business Wire October 27, 2022

Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient

Business Wire October 24, 2022

Therapeutic Solutions International Granted Landmark United States Patent on Ability of QuadraMune® Nutraceutical to Repair Injured Brains

Business Wire October 10, 2022

Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection

Business Wire October 3, 2022

Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial

Business Wire September 20, 2022

Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder

Business Wire September 19, 2022

Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)

Business Wire September 12, 2022

Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome

Business Wire August 29, 2022

Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome

Business Wire August 25, 2022

Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte(TM) on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches

Business Wire August 12, 2022

Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells

Business Wire July 28, 2022

Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell(TM) Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial

Business Wire July 18, 2022

John Hopkin's University Publishes Efficacy of QuadraMune(TM) Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

Business Wire May 27, 2022

Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board

Business Wire May 25, 2022

Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial

Business Wire May 23, 2022

Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell(TM) for Treatment of COPD

Business Wire May 12, 2022